Osteoporosis Prevention in Early Stage Breast Cancer
Project Number5K07CA095597-02
Former Number1K23CA095597-01
Contact PI/Project LeaderHERSHMAN, DAWN
Awardee OrganizationCOLUMBIA UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
DESCRIPTION (provided by applicant): In the United States, more than 2
million women are living with a history of breast cancer. Because of past
advances in chemotherapy, the vast majority of women diagnosed with breast
cancer will survive for many years, but they will also have increased risk for
long-term complications related to estrogen deficiency, lymph node dissection,
and other effects of chemotherapy on health tissue Evidence suggests that
women who survive breast cancer have an increased risk for osteoporosis. This
risk is highest for premenopausal women who become menopausal with
chemotherapy. However, controversy exists regarding the extent of bone loss,
and only a few studies have evaluated mechanisms to prevent it. A double-
blind randomized control trial of weekly alendronate in premenopausal women
treated with adjuvant chemotherapy for breast cancer will be performed to
define and compare the changes in BMD and bone turnover that occur during and
after adjuvant chemotherapy for breast cancer. We expect to characterize the
natural history of bone loss during chemotherapy and define risk factors that
contribute to this loss in newly diagnosed premenopausal breast cancer
patients. By defining factors that predict accelerated bone loss we hope to
help guide preventive therapy. With the results of this trial, cost-
effectiveness of bisphosphonate treatment will be modeled. We expect that
bisphosphonates will significantly reduce the rate of bone loss in this
patient population and that bisphosphonate use for the prevention of
osteoporosis and its related complications will be cost-effective. The
training portion of this proposal includes regular mentoring with Dr. Karen
Antman and Dr. Elizabeth Shane; extensive interaction with Dr. Alfred Neugut,
Dr. Victor Grann, and Dr. Richard Gralla; and continued formal coursework at
the Mailman School of Public Health at Columbia University. My goal as an
independent investigator is to conduct clinical research that will identify
approaches to cancer treatment that will minimize toxic effects, prevent long-
term complications, and maximize survival, quality of life, and cost-
effectiveness.
No Sub Projects information available for 5K07CA095597-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K07CA095597-02
Patents
No Patents information available for 5K07CA095597-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K07CA095597-02
Clinical Studies
No Clinical Studies information available for 5K07CA095597-02
News and More
Related News Releases
No news release information available for 5K07CA095597-02
History
No Historical information available for 5K07CA095597-02
Similar Projects
No Similar Projects information available for 5K07CA095597-02